-
CDE Releases 73rd Batch of Chemical Generic Reference Preparations with Updates
•
The Center for Drug Evaluation (CDE) has released the 73rd batch of chemical generic reference preparations, marking a significant update in the standardization of generic drugs. This batch includes 31 new specifications, an addition of 57 specifications, and updates to 12 previously published specifications, enhancing the reference framework for chemical…
-
Lee’s Pharmaceutical Holdings Ltd Reports H1 2023 Revenue Dip Amid Product Portfolio Growth
•
China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) has released its financial report for the first half of 2023, recording revenues of HKD 512 million (USD 65.2 million), marking a year-on-year (YOY) decrease of 21.1%. The decline is primarily attributed to product rights expiration, falling sales volumes, and the devaluation of…
-
Watchmaker Genomics and Exact Sciences Corporation Ink Deal to Advance TAPS Technology
•
US-based Watchmaker Genomics has announced a multi-year, co-exclusive agreement with compatriot firm Exact Sciences Corporation to develop and commercialize the breakthrough DNA methylation analysis technology known as TET-assisted pyridine borane sequencing (TAPS). Watchmaker will utilize its expertise in engineering DNA-modifying enzymes to enhance the TAPS chemistry, enabling advanced applications such…
-
XtalPi Inc. Partners with Edelweiss Connect to Revolutionize Skincare Safety Assessment
•
Sino-US artificial intelligence (AI) firm XtalPi (QuantumPharm, HKG: 2228) has announced a strategic partnership with Edelweiss Connect, a Swiss company specializing in next-generation product design and risk assessment solutions. This collaboration aims to leverage the unique strengths of both companies in chemical and pharmaceutical safety assessment, technology platforms, and market…
-
Takeda Secures Exclusive Rights to ImmunoGen’s Elahere in Japan Through New Agreement
•
Japanese pharmaceutical company Takeda (TYO: 4502) has entered into an exclusive collaboration and license agreement with ImmunoGen (NASDAQ: IMGN) to develop and commercialize ImmunoGen’s antibody-drug conjugate (ADC) Elahere (mirvetuximab soravtansine) in Japan. Elahere has received accelerated approval in the United States for the treatment of FRα-positive platinum-resistant epithelial ovarian, fallopian…
-
Johnson & Johnson Reports H1 2023 Sales Growth Following Kenvue Spinoff
•
Global healthcare giant Johnson & Johnson (J&J; NYSE: JNJ) has released a financial update for the first half of 2023, following the completion of the separation of its consumer healthcare spinoff, Kenvue (NYSE: KVUE), into an independent company. The document reveals that H1 2023 global sales reached USD 42.4 billion,…
-
Zhejiang Dian Diagnostics Reports 2023H1 Revenue Dip, Strategic Expansion Continues
•
China-based Zhejiang Dian Diagnostics Co., Ltd (SHE: 300244) has released its financial report for the first half of 2023, recording revenues of RMB 6.842 billion (USD 938.7 million), marking a year-on-year (YOY) decrease of 36.37%. Net profits were reported at RMB 453 million, reflecting a significant YOY decrease of 75.89%.…
